Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . A SINO BIOPHARMACEUTICAL LIMITED 中國 生物 製藥 有限公司 ( Incorporated in the Cayman Islands with limited liability ) Website : www.sbpgroup.com ( Stock code : 1177 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 FINANCIAL HIGHLIGHTS Revenue Profit attributable to owners of the parent For the six months ended 30 June 2026 2025 Change RMB'Billion RMB'Billion % 19.44 17.57 + 10.6 % As reported ( Note 1 ) 3.43 3.39 + 1.4 % Underlying profit ( Note 2 ) 3.34 3.09 + 8.1 % Underlying profit excluding dividend income from Sinovac LS ( Note 2 ) 3.34 1.74 + 92.3 % Sales of total innovative drugs and out - licensing 8.79 6.09 + 44.3 % Share of revenue 45.2 % 34.7 % Sales of innovative drugs ( Note 3 ) Share of revenue 7.81 40.2 % 6.05 34.4 % + 29.2 % Sales of out - license Share of revenue 0.98 5.0 % 0.04 + 2,101.9 % 0.3 % The board of directors of the Company has declared the payment of an interim dividend of HK7 cents per share for the six months ended 30 June 2026 . 1